Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study

This study is testing a combination of two drugs — pembrolizumab (an immunotherapy) and ataluren (a drug that helps the body read through certain genetic errors) — for people with metastatic colorectal cancer or endometrial (uterine) cancer. It focuses on patients with specific genetic markers in their tumors (pMMR or dMMR). **You may be eligible if...** - You are 18 or older - You have metastatic colorectal cancer and have received at least one prior chemotherapy regimen, OR you declined palliative chemotherapy - OR you have metastatic endometrial cancer with a dMMR genetic marker - You have measurable disease on imaging - You have a life expectancy greater than 3 months - Your organ function is adequate - You are willing to provide a tumor biopsy sample **You may NOT be eligible if...** - You have active autoimmune disease requiring treatment - You have had prior treatment with pembrolizumab or similar immunotherapy - You have severe liver or kidney dysfunction - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.